Expression Therapeutics

8 articles about Expression Therapeutics

• Expression Therapeutics to Present at the 2022 BIO CEO & Investor Conference

  2/8/2022

  Expression Therapeutics, Inc. announced that Chief Executive Officer, Dr. Mohan Rao, was selected to present at the BIO CEO & Investor Conference in New York City from February 14-16 and participate in one-on-one investor meetings.

• Expression Therapeutics Celebrates Opening of Cell and Gene Therapy Manufacturing Facility in Ohio

  12/17/2021

  Expression Therapeutics, Inc., a fully integrated clinical stage biotechnology company developing novel cell and gene therapies celebrates the opening of its state-of-the-art 43,000 square foot cell and viral vector manufacturing facility in Cincinnati, Ohio.

• Expression Therapeutics Announces Success in Developing a Stem Cell Lentiviral Gene Therapy for Hemophagocytic Lymphohistiocytosis (HLH)

  8/24/2020

  Primary HLH is a family of devastating primary immune deficiencies with limited treatment options and no gene therapies under clinical testing. Expression Therapeutics has developed a promising and potentially curative gene therapy candidate for familial hemophagocytic lymphohistiocytosis (HLH) type 3 (FHL3). Untreated, FHL3 presents as a

• Expression Therapeutics Announces Bill Swaney as VP of Manufacturing and the Construction of Cell and Gene Therapy Manufacturing

  7/30/2020

   Expression Therapeutics has announced the appointment of Bill Swaney as the Vice President of Manufacturing. He comes to Expression Therapeutics from the Cincinnati Children's Hospital Medical Center where he was the Director of the Vector Production Facility & Viral Vector Core. Mr. Swaney is an internationally recognized expert in GM

• Expression Therapeutics Announces IND Approval by the FDA for Hemophilia A Gene Therapy

  5/26/2020

  Expression Therapeutics has announced that it has received clearance by the United States Food and Drug Administration (FDA) to proceed following review of its Investigational New Drug Application (IND) for clinical testing of its novel lentiviral vector-based gene therapy — ET3 — for hemophilia A. Hemophilia A is the most common severe congen

• ASC Therapeutics Licenses Critical Technologies for Hemophilia A Gene Therapy from Expression Therapeutics

  5/16/2019

  ASC Therapeutics, A Division of Applied StemCell, Inc., announced that it has obtained an exclusive therapeutics license from Expression Therapeutics, LLC for coagulation factor VIII expression technologies including a highly compact, yet potent, liver-directed promoter and matching liver-codon optimized factor VIII transgene for adeno-associated viral vector gene therapy of hemophilia A.

• Expression Therapeutics Selects Advanced BioScience Laboratories, Inc. To Support Cell Line Development For Hemophilia A Factor VIII Infusion Therapy

  8/18/2014

• Lentigen Corporation and Expression Therapeutics Sign Hemophilia Co-Development Agreement

  2/4/2009